PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

New research to investigate higher COVID-19 risk among BAME groups

Six new projects hoping to further improve understanding of the links between ethnicity and susceptibility to COVID-19 are being funded by the NIHR and UK Research and Innovation (UKRI).

The projects will seek to explain and mitigate the disproportionate death rate from COVID-19 among people from Black, Asian and minority ethnic (BAME) backgrounds, including BAME health and social care workers.

The move follows emerging evidence showing people from BAME backgrounds are nearly twice as likely to die of COVID-19 than white people.

Specifically, the projects will receive funding of £4.3 million to: explore the impact of the virus specifically on migrant and refugee groups; work with BAME communities to create targeted, digital health messages; introduce a new framework to ensure the representation of people from BAME backgrounds in COVID-19 clinical trials; and the creation of one the UK’s largest COVID-19 cohorts.

“With evidence showing that people from Black, Asian and minority ethnic backgrounds are more severely affected by COVID-19, it is critical that we understand what factors are driving this risk to address them effectively,” said chief medical officer for England and head of the NIHR Professor Chris Whitty.

“The diverse range of projects funded by the NIHR and UKRI will help examine this association in detail, so that new treatments and approaches to care can be developed to target the ethnicities most at risk. This research will have embedded patient and public involvement with Black, Asian and minority ethnic groups at all stages of the research.”

“Urgent action must be taken to determine and address the factors underlying this disparity,” added UKRI chief executive, Professor Dame Ottoline Leyser. “There is unlikely to be a simple answer and we must consider all possibilities, including the role of racial and social inequalities, so that we can save as many lives as possible during this pandemic and any future outbreaks.”

The NIHR is also working to encourage people from BAME backgrounds to take part in COVID-19 research and ensure that researchers include these communities in their studies.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026